Invivo Therapeutics Holdings Corp (NASDAQ:NVIV) was the target of a significant drop in short interest during the month of September. As of September 30th, there was short interest totalling 17,100 shares, a drop of 54.6% from the August 30th total of 37,700 shares. Approximately 0.2% of the company’s shares are short sold. Based on an average trading volume of 41,700 shares, the short-interest ratio is currently 0.4 days.
Shares of NVIV traded up $0.02 during trading on Friday, reaching $0.50. 6,191 shares of the company traded hands, compared to its average volume of 15,944. Invivo Therapeutics has a twelve month low of $0.45 and a twelve month high of $2.75. The stock has a market cap of $4.56 million, a PE ratio of -0.22 and a beta of 1.54. The stock has a 50-day simple moving average of $0.57 and a 200-day simple moving average of $0.90. The company has a quick ratio of 5.72, a current ratio of 5.72 and a debt-to-equity ratio of 0.11.
Invivo Therapeutics (NASDAQ:NVIV) last announced its quarterly earnings results on Tuesday, August 13th. The biotechnology company reported ($0.34) earnings per share for the quarter. On average, equities research analysts predict that Invivo Therapeutics will post -1.25 EPS for the current year.
InVivo Therapeutics Holdings Corp., a research and clinical-stage biomaterials and biotechnology company, engages in developing and commercializing biopolymer scaffolding devices for the treatment of spinal cord injuries. It is developing Neuro-Spinal Scaffold implant, an investigational bioresorbable polymer scaffold for implantation at the site of injury within a spinal cord.
Featured Story: Technical Analysis of Stocks, How Can It Help
Receive News & Ratings for Invivo Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Invivo Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.